Cardiomyopathy Trial, Recruiting (NCT06091475)

Cardiomyopathy Trial, Recruiting NCT06091475 Sponsor: Imperial College London Condition: Cardiomyopathy

Printed from Voxsanity (voxsanity.com.au) — NCT06091475 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.

Back to Cardiomyopathy

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

You have been diagnosed with dilated cardiomyopathy (a condition where the heart muscle is weakened and the heart becomes enlarged)
Your heart pumping function was previously measured as less than 40% (meaning the heart was not pumping well)
Your heart pumping function has since recovered to above 50%, and your heart size is now normal
A blood test result called NT-pro-BNP (a marker of heart strain) is below 250ng/L
You have no symptoms, or only very mild symptoms, from your heart condition (known as NYHA Class I)
Your heart is beating in a normal, regular rhythm (called sinus rhythm)
You are currently taking a beta-blocker AND one of the following blood pressure/heart medicines: an ACE inhibitor, an ARB, or sacubitril-valsartan, PLUS at least one of either a mineralocorticoid receptor antagonist or an SGLT2 inhibitor (confirm exact medicines with trial site)

Who may not be able to join:

You have an irregular heart rhythm called atrial fibrillation
You have previously had a serious abnormal heart rhythm (sustained ventricular tachycardia or ventricular fibrillation)
You carry a known harmful gene variant in one of these specific genes: LMNA, DSP, FLNC, or RBM20
A close family member (parent, sibling, or child) died suddenly from a heart problem or heart failure before the age of 50
You are unable to have an MRI scan of your heart (for example, due to a pacemaker or severe claustrophobia)
Your kidney function is below a certain level (eGFR under 60 ml/min, as measured by a blood test)
You are planning to become pregnant
You currently have active inflammation of the heart muscle
You have diabetes and are already being treated with an SGLT2 inhibitor medication for that reason
You have a certain combination of reduced kidney function and a raised level of protein in your urine (confirm specific values with trial site)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.

Last synced 27 July 2026

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Brian P Halliday, MBChB, Imperial College London, Royal Brompton Hospital

Phone: 02073528121

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Voxsanity

Clinical trials and treatments, explained plainly · voxsanity.com.au

Date:

To: My Doctor

Re: Clinical trial enquiry

I am writing to enquire about the following clinical trial which may be relevant to my care:

Trial: NCT06091475

Sponsor: Imperial College London

Phase: Not Applicable

Status: Recruiting

Condition: Cardiomyopathy

Trial contact: 02073528121

More information: https://clinicaltrials.gov/study/NCT06091475

Eligibility summary (AI generated)

Written by an AI model from the ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

You have been diagnosed with dilated cardiomyopathy (a condition where the heart muscle is weakened and the heart becomes enlarged)
Your heart pumping function was previously measured as less than 40% (meaning the heart was not pumping well)
Your heart pumping function has since recovered to above 50%, and your heart size is now normal
A blood test result called NT-pro-BNP (a marker of heart strain) is below 250ng/L
You have no symptoms, or only very mild symptoms, from your heart condition (known as NYHA Class I)
Your heart is beating in a normal, regular rhythm (called sinus rhythm)
You are currently taking a beta-blocker AND one of the following blood pressure/heart medicines: an ACE inhibitor, an ARB, or sacubitril-valsartan, PLUS at least one of either a mineralocorticoid receptor antagonist or an SGLT2 inhibitor (confirm exact medicines with trial site)

Who may not be able to join:

You have an irregular heart rhythm called atrial fibrillation
You have previously had a serious abnormal heart rhythm (sustained ventricular tachycardia or ventricular fibrillation)
You carry a known harmful gene variant in one of these specific genes: LMNA, DSP, FLNC, or RBM20
A close family member (parent, sibling, or child) died suddenly from a heart problem or heart failure before the age of 50
You are unable to have an MRI scan of your heart (for example, due to a pacemaker or severe claustrophobia)
Your kidney function is below a certain level (eGFR under 60 ml/min, as measured by a blood test)
You are planning to become pregnant
You currently have active inflammation of the heart muscle
You have diabetes and are already being treated with an SGLT2 inhibitor medication for that reason
You have a certain combination of reduced kidney function and a raised level of protein in your urine (confirm specific values with trial site)

Important: Always verify eligibility with the trial site directly before applying.

Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.

This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 27 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.

Trial details

Status

Recruiting

Phase

Not Applicable

Sponsor

Imperial College London

Registry

ClinicalTrials.gov

Start date

2 December 2023

Est. completion

15 August 2026

Where this trial is recruiting

🇬🇧 United Kingdom

Primary endpoints

Heart Failure Relapse assessed through left ventricular ejection fraction (LVEF); Heart Failure Relapse assessed through pro-BNP; Number of patients with heart failure Relapse assessed through signs of heart failure; Number of patients with heart failure Relapse assessed through symptoms of heart failure

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov